Bristol Myers Squibb shared a post on LinkedIn:
“The science of cancer care continues to evolve – and ASCO 2026 is where we’ll show just how far we’ve come and where we are headed.
This year, we will share data from more than 50 abstracts at the American Society of Clinical Oncology (ASCO)® Annual Meeting in Chicago, IL, spanning 10+ cancer types across our oncology portfolio and next-generation pipeline.
From industry-leading targeted protein degradation research to real-world cell therapy outcomes, our presentations reflect our ongoing dedication to redefining what’s possible for people living with some of the most challenging cancers.
Read more about the data we are presenting this year.”
Other articles about ASCO on OncoDaily.